Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of heat shock protein gp96 in treatment on autoimmune hemolytic anemia

A technology of heat shock protein and autoimmunity, which is applied in the application field of heat shock protein gp96 in the treatment of autoimmune hemolytic anemia, and can solve problems such as the application of heat shock protein that has not been reported

Inactive Publication Date: 2017-07-25
FOSHAN HEAT SHOCK BIOTECH CO LTD
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no report on the application of heat shock protein gp96 in the treatment of autoimmune hemolytic anemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of heat shock protein gp96 in treatment on autoimmune hemolytic anemia
  • Use of heat shock protein gp96 in treatment on autoimmune hemolytic anemia
  • Use of heat shock protein gp96 in treatment on autoimmune hemolytic anemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Obtaining of heat shock protein gp96

[0042] (1) Purification of gp96 protein from human placenta tissue

[0043] 1. Tissue homogenate

[0044] Homogenization buffer formula: add PMSF (phenylmethylsulfonyl fluoride, molecular formula C 7 h 7 FO 2 S) to a final concentration of 1 mM (prepared in a beaker on ice: PMSF decomposes in an aqueous solution within a few hours, and the solution cannot be left overnight).

[0045] Put the beaker on ice, quickly cut the human placenta tissue into fragments with a diameter of about 1-2 mm in the beaker, and then add homogenization buffer 8 times the weight of the tissue. Stir the tissue pieces into a glass homogenizer, homogenize until the bottom tissue pieces disappear, and then homogenize up and down for more than 15 times. The homogenate was poured into a centrifuge tube, centrifuged at 50,000 g for 60 min, and the supernatant was added to 1 / 10 volume of 10×PBS (pH7.5, 200 mM NaCl) for ConA-Sepharose chromatograp...

Embodiment 2

[0098] Example 2 Determination of the dosage of human heat shock protein gp96 in activated regulatory T cells

[0099] 1. Group immunization of mice 100 mice weighing 18-22 g were randomly divided into placenta gp96 treatment group 1, placenta gp96 treatment group 2, placenta gp96 treatment group 3, yeast gp96 treatment group 1, gp96 treatment group 2, yeast gp96 treatment group Treatment group 3, insect gp96 treatment group 1, insect gp96 treatment group 2, insect gp96 treatment group 3 and control group (10 in each group) were processed as follows:

[0100] (1) placenta gp96 treatment group 1: on the first day of the experiment, the solution of gp96 extracted from human placenta tissue in Example 1 was injected intraperitoneally; on the eighth day of the experiment, the solution of gp96 extracted from human placenta tissue in Example 1 was injected intraperitoneally again; On the 22nd day of the experiment, the solution of gp96 extracted from human placenta tissue in Example...

Embodiment 3

[0124] Example 3 Application of gp96 in the treatment of autoimmune hemolytic anemia

[0125] 1. Antibody titer analysis of autoerythrocytes

[0126] 1. Mice were immunized in groups. 120 six-week-old healthy BALB / C mice with a body weight of 18-22 g were randomly divided into 4 groups (30 mice in each group), and were treated as follows:

[0127] gp96 treatment group 1: on the first day of the experiment, intraperitoneally inject the solution of gp96 extracted from human placenta tissue prepared in Example 1; on the eighth day of the experiment, intraperitoneally inject the solution of gp96 extracted from human placenta tissue prepared in Example 1 again; on the 22nd day of the experiment , and intraperitoneally inject the solution of gp96 extracted from human placenta tissue prepared in Example 1 again. The dose of each injection was 200μg gp96 / only.

[0128] gp96 treatment group 2: according to the operation steps of gp96 treatment group 1, only gp96 protein for injection...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a use of a heat shock protein gp96 in treatment on autoimmune hemolytic anemia and belongs to the technical field of protein engineering and biomedical application. The amino acid sequence of the heat shock protein gp96 is shown in the formula of SEQ ID NO. 2 or is a specific fragment of the amino acid sequence shown in the formula of SEQ ID NO. 2. The heat shock protein gp96 can induce the production of regulatory T cells, can reduce anti-erythrocyte antibody titer, can improve the number of red blood cells and content of hemoglobin, can be used for preparation of a drug for treating autoimmune hemolytic anemia and has a wide application prospect.

Description

technical field [0001] The invention relates to the technical field of protein engineering and biomedical application, in particular to the application of heat shock protein gp96 in the treatment of autoimmune hemolytic anemia. Background technique [0002] Autoimmune hemolytic anemia (Autoimmune hemolytic anemia, AIHA) is a type of hemolytic anemia caused by the disorder of immune function regulation in the body, the production of autoantibodies and (or) complement adsorption on the surface of red blood cells, and the accelerated destruction of red blood cells through antigen-antibody reactions. Autoimmune hemolytic anemia can be divided into warm antibody type and cold antibody type according to the optimum temperature required for the antibody to act on the red blood cell membrane. Currently, glucocorticoids are commonly used in the treatment of human autohemolytic anemia, which play a role by inhibiting the phagocytosis and processing of antigens by macrophages and inhib...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P37/02A61P7/06
CPCA61K38/1709
Inventor 孟颂东李鑫鞠莹
Owner FOSHAN HEAT SHOCK BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com